ライフサイエンスコーパス: tolerance test

1 cose area under the curve in an oral-glucose-tolerance test).

2 raction from a mixed-meal or an oral glucose tolerance test).

3 ., a glucose clamp or an intravenous glucose tolerance test).

4 r glucose was measured after an oral glucose tolerance test.

5 h type 2 diabetes before and after a glucose tolerance test.

6 ostasis measured by means of an oral glucose tolerance test.

7 ified frequently sampled intravenous glucose tolerance test.

8 lerance after oral dosing in an oral glucose tolerance test.

9 es assessed by using a standard oral glucose tolerance test.

10 n the basal state and during an oral glucose tolerance test.

11 sing the Matsuda method from an oral-glucose-tolerance test.

12 ere then subjected to an intravenous glucose tolerance test.

13 SI was determined by intravenous glucose tolerance test.

14 men, respectively, completed an oral glucose tolerance test.

15 on, fasting glucose measurement, and glucose tolerance test.

16 nsitivity as measured by intravenous glucose tolerance test.

17 lso increases in response to an oral glucose tolerance test.

18 continued through a 3-h intravenous glucose tolerance test.

19 lin sensitivity was assessed by oral glucose tolerance test.

20 ing the insulin-modified intravenous glucose tolerance test.

21 was confirmed through an intravenous glucose tolerance test.

22 from frequently sampled intravenous glucose tolerance test.

23 ential postprandial responses to an oral fat tolerance test.

24 ucose, and urinary galactose after a lactose tolerance test.

25 d fasting glucose determined by oral glucose tolerance test.

26 rations were measured during an oral glucose tolerance test.

27 blood and urine sampling and an oral glucose tolerance test.

28 t hemoglobin A1c testing and an oral glucose tolerance test.

29 rgery, as assessed by an intravenous glucose tolerance test.

30 pes were derived from a 5-point oral glucose tolerance test.

31 tivity to insulin action measured by insulin tolerance test.

32 abetes; mice were then given an oral glucose tolerance test.

33 sting blood glucose measurements and glucose tolerance tests.

34 cemic clamp and intravenous and oral glucose tolerance tests.

35 using both the oral and intravenous glucose tolerance tests.

36 v 131.7 mumol/L; P = 0.09), and oral glucose tolerance tests.

37 es status was assessed by using oral-glucose-tolerance tests.

38 ively by intraperitoneal glucose and insulin tolerance tests.

39 te ratings were obtained throughout the meal tolerance tests.

40 ather than insulin resistance during insulin tolerance tests.

41 uired from human subjects undergoing glucose tolerance tests.

42 e was evaluated with intraperitoneal glucose tolerance tests.

43 icipants were diagnosed by 75 g oral glucose-tolerance tests.

44 n kinetics were calculated from oral glucose tolerance tests.

45 the obese subjects was documented by glucose tolerance testing.

46 curve for glucose during 2-hour oral glucose tolerance testing.

47 ut not after adjusting for positive exercise tolerance testing.

48 ell function, which was evaluated by glucose tolerance testing.

49 ex (DI) were assessed by intravenous glucose tolerance testing.

50 ose intolerant as determined by oral glucose tolerance testing.

51 ured by nonfasting blood glucose and glucose tolerance testing.

52 ive abnormal glucose tolerance (oral glucose tolerance test 1-h glucose >=155 and 2-h glucose <200 mg

53 After 6 wk, a 75-g oral-glucose-tolerance test (13C-labeled) and a subsequent fasting ch

54 eople who were screened with an oral glucose tolerance test, 196 (15%) had impaired glucose tolerance

55 ing the first 30 minutes of the oral glucose tolerance test 2 years later.

56 d responses in LAdrKO mice during a glucagon tolerance test (250 ug/kg intraperitoneally).

57 lthy control subjects underwent a mixed-meal tolerance test (350 kcal) using a dual glucose tracer me

58 ide level in response to a 4-hour mixed-meal tolerance test (4-hour C-peptide AUC) at week 52.

59 (insulin area under the curve during glucose tolerance test 609 +/- 103 vs. 313 +/- 66 ng mL(-1) min)

60 t exendin(9-39)NH(2) During 4-h oral glucose tolerance tests (75 g) combined with an ad libitum meal

61 All underwent an oral glucose tolerance test, a liver panel, and a lipid profile.

62 glucose than wild-type (WT) mice in pyruvate tolerance tests, accompanied with enhanced expression of

63 nsulin and glucose after a 75-g oral-glucose-tolerance test after 4 mo of treatment.

64 the early postpartum period via oral glucose tolerance testing after GDM, which is a time-consuming a

65 se disappearance rate on intravenous glucose tolerance test, all of which worsened minimally thereaft

66 glucose concentrations and 2-h oral glucose tolerance tests among a cross-section of adults aged 30

67 or glucose, and insulin from an oral glucose tolerance test) analysed in the intention-to-treat popul

68 lthy control subjects to a 75-g oral glucose tolerance test and a corresponding isoglycemic intraveno

69 avenous [6,6-2H2]-, oral 13C-labeled glucose tolerance test and a polysomnographic recording were per

70 color Doppler echocardiography, oral glucose tolerance test and blood biomarkers analyses were perfor

71 nal diabetes (diagnosed with an oral glucose tolerance test and by criteria from the International As

72 g the frequently sampled intravenous glucose tolerance test and insulin sensitivity using the hyperin

73 A glucose tolerance test and insulin tolerance test showed that 25

74 ition index were measured after oral glucose tolerance test and isoglycemic IV glucose injection (IGI

75 were determined from an intravenous glucose tolerance test and minimal modeling.

76 rticipants underwent a standard oral glucose tolerance test and provided detailed clinical, sociodemo

77 Participants underwent an oral glucose tolerance test and retinal imaging at 26-28 weeks gestat

78 story of T2DM (FH+) received an oral glucose tolerance test and two-step hyperglycemic clamp (100 and

79 ing the first 30 minutes of the oral glucose tolerance test and using the area under the curve of ins

80 Yet in insulin tolerance tests and euglycemic clamp experiments, NTE-1

81 ter beta3-AR agonist treatment, oral glucose tolerance tests and euglycemic clamps were performed, an

82 Results from in vivo glucose and insulin tolerance tests and ex vivo analyses revealed fasting hy

83 de of insulin secretion were used in glucose tolerance tests and in positron emission tomography anal

84 uppression of plasma FFA during oral glucose tolerance tests and insulin clamp in obese NGT and T2DM

85 Glucose or insulin tolerance tests and insulin signaling were performed in

86 olism investigations showed abnormal glucose tolerance tests and low HDL values in some patients, and

87 Intravenous-glucose-tolerance tests and oral-glucose-tolerance test (OGTT) a

88 cose area under the curve in an oral glucose tolerance test, and AcAc predicted the conversion to typ

89 lipid levels, the results of an oral glucose tolerance test, and blood pressure were used to characte

90 ) using a clinical examination, oral glucose tolerance test, and gene expression and DNA methylation

91 lood glucose measurement, a 2-h oral-glucose-tolerance test, and record linkage to a reimbursement re

92 ma glucose concentrations in an oral glucose tolerance test, and thus impaired beta cell function.

93 l laboratory testing, including oral glucose tolerance test, and ultrasonographic investigations of f

94 cardiac magnetic resonance imaging, exercise tolerance testing, and biomarker assessment.

95 nd C-peptide levels, and glucose and insulin tolerance tests, and genetic deletion of hepatic FoxO1 r

96 Oral glucose tolerance tests, mixed-meal tolerance tests, and glucose-potentiated arginine tests

97 nnaires, clinical measurements, oral glucose tolerance tests, and laboratory examinations were carrie

98 ear magnetic resonance spectroscopy, glucose tolerance tests, and plasma analyses.

99 We used fasting plasma glucose, glucose tolerance tests, and self-reported diabetes diagnoses or

100 easurement of glucose turnover; oral glucose tolerance test; and a liver biopsy.

101 nd insulin during an intraperitoneal glucose tolerance test; and Glut4 and ApoE expression in VAT.

102 ears that included 2-hour, 75-g oral glucose tolerance testing; anthropometry; and interviews.

103 According to oral glucose tolerance testing, approximately 14% of patients with Gi

104 perglycaemia defined without an oral glucose tolerance test as impaired fasting glucose (IFG) and hig

105 in impaired insulin secretion during glucose tolerance tests as well as hyperglycemic clamps.

106 a and whole-body insulin resistance (insulin tolerance test) as well as muscle oxidative stress, infl

107 She underwent tolerance tests, as food-dependent exercise-induced anap

108 tide response was measured with a mixed meal tolerance test at 75 and 365 days after transplant.

109 l metabolism obtained during an oral glucose tolerance test at approximately 28 weeks' gestation, we

110 Participants underwent an oral glucose tolerance test at baseline and after 2 years to assess g

111 rface area burned, underwent an oral glucose tolerance test at discharge.

112 ulin will be measured during an oral glucose tolerance test at weeks 0 and 12.

113 Glucose tolerance testing at discharge offers an opportunity for

114 s was performed with the use of oral glucose-tolerance tests at 6-month intervals.

115 Oral glucose tolerance tests at baseline and after 1 year of treatmen

116 Oral glucose tolerance tests at discharge revealed that metformin sig

117 (GDM) during pregnancy from clinical glucose tolerance tests at median 28.1 weeks gestation.

118 and C-peptide measured by using oral-glucose-tolerance tests at the end of each diet.

119 All women underwent 75-g oral glucose tolerance tests at ~26 weeks of gestation; we used gluco

120 RSM with three predonation RFs (oral glucose tolerance test, basal insulin, fasting plasma glucose) a

121 nt of insulin resistance and an oral glucose tolerance test-based index (Matsuda insulin sensitivity

122 mic-hyperinsulinemic clamp- and oral glucose tolerance test-based measures of insulin resistance and

123 YGB were studied with an intravenous glucose tolerance test before surgery and at 5-12% weight loss p

124 stionnaires, by fasting and 2-h oral-glucose-tolerance test blood glucose measurement at re-examinati

125 stionnaires; by fasting and 2-h oral-glucose-tolerance-test blood glucose measurement at re-examinati

126 S(I) (frequently sampled intravenous glucose tolerance test), body composition (dual-energy X-ray abs

127 on is crucial, and the modified oral glucose tolerance test, but not gastric emptying testing, is use

128 (beta = 0.46, P = 0.00090) post oral glucose tolerance test, but only the latter passed Bonferroni co

129 The glucose tolerance test clarified that the complex retained blood

130 d fasting hyperglycemia and impaired glucose tolerance test compared with wild-type mice.

131 BV at rest and during an intravenous glucose tolerance test demonstrated a sustained increase from 4

132 d glucose production from pyruvate (pyruvate tolerance test), demonstrating defective hepatic glucone

133 In the independent cohort, only oral glucose tolerance test-derived indexes were associated with live

134 fasting glucose or insulin, or oral glucose tolerance test-derived measures.

135 nsitivity, show improvements in oral glucose tolerance tests, display reduced adipose tissue inflamma

136 did not change glucose tolerance or insulin tolerance tests done with pharmacological levels of insu

137 nal cohort of women with GDM who had glucose tolerance tested during the early postpartum period.

138 In insulin tolerance test, exogenous insulin-induced suppression of

139 plasma glucose levels after an oral glucose tolerance test, fasting plasma insulin levels, insulin r

140 plasma glucose levels after an oral glucose tolerance test, fasting plasma insulin levels, insulin r

141 Oral tolerance tests for vitamin D2 (1,000 IU vitamin D2/kg)

142 y the frequently sampled intravenous glucose tolerance test (four cohorts) or euglycemic clamp (three

143 r the curve C-peptide response to mixed meal tolerance test from baseline to 12 months.

144 to a frequently sampled intravenous glucose tolerance test (FSIGT) with the stimulator on and with t

145 fied, frequently sampled intravenous glucose tolerance test (FSIGT), we estimated hepatic versus extr

146 ose tolerance (measured with an oral glucose tolerance test given after 90 min) and meal size (ad-lib

147 During glucose tolerance tests, glucose disposal was enhanced in SIRT2

148 recognition, grip strength, rotarod, glucose tolerance test (GTT) and insulin tolerance test (ITT), b

149 cose >/=200 mg/dL during a 75-g oral glucose tolerance test had a definite diagnosis of type 2 diabet

150 d with glucose responses during oral glucose tolerance testing, HbA1c, beta-cell function, and insuli

151 plasma glucose levels after an oral glucose tolerance test (Hedges g = 0.61; 95% CI, 0.16 to 1.05; P

152 -fasting plasma glucose levels, oral glucose tolerance tests, hemoglobin A1C levels, and/or antidiabe

153 during oral but not intraperitoneal glucose tolerance tests, highlighting the involvement of intesti

154 T) followed by a 75-gram 2-hour oral glucose tolerance test if GCT result was >/=7.8 mmol/L.

155 t, ABA paradigm, and intraperitoneal glucose tolerance test (IGTT).

156 In the oral glucose tolerance test, IL-1betaAb-treated CDs-HSD rats showed l

157 high risk women for subsequent oral glucose tolerance testing improves dysglycemia detection in Asia

158 with sham stimulation during an oral glucose tolerance test in a randomized, single-blind, cross-over

159 In the starch tolerance test in mice, fraction 16C reduced blood gluco

160 ife and glucose tolerance in an oral glucose tolerance test in rodents.

161 inings and performed intraperitoneal glucose tolerance testing in transgenic mice overexpressing hZnT

162 d sensitivity were defined from oral-glucose-tolerance tests in 86 overweight and obese subjects with

163 eritoneal sensors during intravenous glucose tolerance tests in eight swine.

164 lucose excursions in intraperitoneal glucose tolerance tests in mice with streptozotocin-induced (typ

165 ucture and function, intraperitoneal glucose tolerance test (IPGTT) for glucose metabolism, insulin t

166 as measured using an intraperitoneal glucose tolerance test (IPGTT).

167 equently assessed by intraperitoneal glucose tolerance test (IPGTT).

168 entrations during an intraperitoneal glucose tolerance test (ipGTT).

169 lucose measurements, intraperitoneal glucose tolerance testing (IPGTT), and human C-peptide secretion

170 er training using an intraperitoneal insulin tolerance test (ITT) and BP was assessed before and afte

171 test (IPGTT) for glucose metabolism, insulin tolerance test (ITT), and histology of cardiac structure

172 od, glucose tolerance test (GTT) and insulin tolerance test (ITT), body composition, and energy expen

173 al model analysis of the intravenous glucose tolerance test (IVGTT) to document progression of resist

174 rance test (OGTT) and an intravenous glucose tolerance test (IVGTT) were performed between the 24th a

175 humans during an in-vivo Intravenous Glucose Tolerance Test (IVGTT).

176 glucose disposal during intravenous glucose tolerance tests (IVGTT) remains critical for stringent e

177 d insulin secretion [via intravenous-glucose-tolerance tests (IVGTTs)].Fifty-four participants comple

178 On the basis of the glucose tolerance test known to be a clinically relevant procedu

179 se and insulin levels during an oral glucose tolerance test; levels of low-density lipoprotein (LDL)

180 Frequently sampled intravenous-glucose-tolerance tests measured insulin sensitivity (SI) and be

181 Oral glucose tolerance tests, mixed-meal tolerance tests, and glucose

182 The patients underwent the mixed meal tolerance test (MMT), hyperinsulinemic-euglycemic clamps

183 atus, and beta cell function by a mixed-meal tolerance test (MMTT) and a hyperglycemia/arginine clamp

184 under the curve (AUC) following a mixed-meal tolerance test (MMTT) and flow cytometry.

185 rations in blood in response to a mixed-meal tolerance test (MMTT) at 1-year follow-up.

186 ype 1 diabetes classified by peak mixed-meal tolerance test (MMTT) C-peptide as negative (<0.007 pmol

187 categorical nature and requires a mixed-meal tolerance test (MMTT).

188 lin secretion was measured with a mixed meal tolerance test (MMTT).

189 AUC C-peptide following a 2-hour mixed-meal tolerance test (MMTT).

190 glucose-potentiated arginine and mixed-meal tolerance tests (MMTTs), respectively, in pancreatic-suf

191 lucose levels were assessed during a glucose tolerance test (n = 2,264).

192 ntifying IGT/NODAT using 2-hour oral glucose tolerance test (n = 66), fructosamine was the most accur

193 and glucose metabolism status (oral glucose tolerance test; normal glucose metabolism [n=1269], pred

194 A 2-hour oral glucose tolerance test of >=140 mg/dL remains the most common cr

195 sults of a 26-28 week gestation oral glucose tolerance test) of women from the Born in Bradford study

196 clamp (40 mU/m(2) . min) and an oral glucose tolerance test (OGTT) (75 g) on separate days.

197 ediabetes onset and the average oral glucose tolerance test (OGTT) 2-h glucose measurement over previ

198 aged 50-65 were subjected to an oral glucose tolerance test (OGTT) and a mixed-meal test (MMT) before

199 prospective clinical study, an oral glucose tolerance test (OGTT) and an intravenous glucose toleran

200 ell function assessed during an oral glucose tolerance test (OGTT) and an isoglycemic intravenous glu

201 g glucose tolerance received an oral glucose tolerance test (OGTT) and euglycemic insulin clamp.

202 ous-glucose-tolerance tests and oral-glucose-tolerance test (OGTT) and hyperinsulinemic-euglycemic cl

203 obin A1C, body composition, the oral glucose tolerance test (oGTT) and the Sweet Taste Test (STT) wer

204 nd whose mothers had a 2-h 75-g oral-glucose-tolerance test (OGTT) at 26-28 weeks of gestation were i

205 nd labeled glucose infusion and oral glucose tolerance test (OGTT) before and 6 months after RDN.

206 beverage consumption during an oral glucose tolerance test (OGTT) for 400 northern European mothers

207 s conventionally confirmed with oral glucose tolerance test (OGTT) in 24 to 28 weeks of gestation, bu

208 of biochemical changes after an oral glucose tolerance test (OGTT) in a community-based population.

209 d that displayed activity in an oral glucose tolerance test (OGTT) in normal and diabetic mice.

210 .4 +/- 0.8 were subjected to an oral-glucose-tolerance test (OGTT) on 4 separate days with the use of

211 n addition to 0-hour and 2-hour oral glucose tolerance test (OGTT) results, with measurement of gluco

212 We analyzed the results of an oral glucose tolerance test (OGTT) routinely performed before surgery

213 Sullivan test (POT) results, an oral glucose tolerance test (OGTT) was performed to diagnose GDM.

214 At each visit, an oral-glucose-tolerance test (OGTT) was performed.

215 An oral glucose tolerance test (OGTT) was used to evaluate glucose contr

216 e, insulin, and GLP-1 during an oral glucose tolerance test (OGTT) were analyzed in individuals with

217 noester (KE) drink before a 2-h oral-glucose-tolerance test (OGTT) would lower blood glucose concentr

218 l participants and underwent an oral glucose tolerance test (OGTT), a hypoglycemia questionnaire, and

219 s is usually performed using an oral glucose tolerance test (OGTT), although a non-fasting, glucose c

220 ncy, participants had an oral glucose (75 g) tolerance test (OGTT), and GDM diagnosis was based on di

221 peak glucose levels in an acute oral glucose tolerance test (OGTT), but this effect was lost upon chr

222 ucose measured 2 h after a 75 g oral glucose tolerance test (OGTT), compared first between the hydroc

223 rols were evaluated using a 2-h oral glucose tolerance test (OGTT), with 7 samples of plasma glucose

224 Herein we describe oral glucose tolerance test (OGTT)-modeled beta-cell function and inc

225 (PLC) 30 minutes before a 75-g oral glucose tolerance test (OGTT).

226 mol/L (>/= 200 mg/dL) during an oral glucose tolerance test (OGTT).

227 subcutaneously 30 min before an oral glucose tolerance test (OGTT).

228 ng actions were tested after an oral glucose tolerance test (OGTT).

229 ired to clear glucose during an oral glucose tolerance test (OGTT).

230 es based on the rarely utilized oral glucose tolerance test (OGTT).

231 livery, parity, maternal age at oral glucose tolerance test (OGTT); Model 2 adjusted for Model 1 cova

232 Postinfusion, a 240-min oral-glucose-tolerance test (OGTT; 75 g) was administered.

233 transplant recipients underwent oral glucose tolerance tests (OGTT) in 2005 to 2006 (baseline) and th

234 ch visits including 2-hour 75-g oral glucose tolerance tests (OGTTs) at study baseline (6-9 weeks pos

235 lenge change in glucagon during oral glucose tolerance tests (OGTTs), hypothesizing that higher postc

236 ibody was administered prior to oral glucose tolerance tests (OGTTs).

237 llected from frequently sampled oral-glucose-tolerance tests (OGTTs).Twenty-seven of 29 recruited par

238 Two consecutive 5-h oral-lipid-tolerance tests (OLTTs) were conducted in 51 healthy adu

239 olism observed in an intraperitoneal glucose tolerance test on male C57BL/6J mice supported this asso

240 esponse to a glucose load applied in glucose tolerance tests on different days, promoted glucose upta

241 n, we performed oral and intravenous glucose tolerance tests on mutation carriers and matched control

242 ollowing intraperitoneal glucose, or insulin tolerance tests, or after mixed nutrient meals.

243 ulin; HbA1c; glucose dynamics during glucose tolerance testing; or in pancreatic islet area or islet

244 uced insulinemic response to an oral-glucose-tolerance test over time with daily breakfast relative t

245 During the oral glucose tolerance test, overfeeding significantly increased endo

246 P = 0.07) and glycemia after an oral-glucose-tolerance test (P = 0.10) trended toward being lower in

247 roved insulin response after an oral glucose-tolerance test (P = 9.8 x 10(-5)), whereas abnormalities

248 All underwent oral glucose tolerance tests pre-LTx and serially post-LTx.

249 e tolerance estimated by a 75-g oral glucose tolerance test result.

250 HFD worsened glucose tolerance test results and caused increased adipocyte si

251 ze; for mice on an HFD, SAP improved glucose tolerance test results and reduced adipocyte size.

252 emic throughout the study, and their glucose tolerance test results were similar to control CD-1 mice

253 On the basis of oral glucose tolerance test results, participants were grouped into t

254 by a frequently sampled intravenous glucose tolerance test.RESULTSChronic mirabegron therapy increas

255 Finally, an intravenous glucose tolerance test revealed higher insulin sensitivity, gluc

256 addition, body weight records and a glucose tolerance test revealed no differences between WT and PA

257 erinsulinemic-euglycemic clamp and a glucose tolerance test revealed no differences in insulin sensit

258 A pyruvate tolerance test revealed that PEMT deficiency greatly att

259 lycemic-euglycemic clamp studies and glucose tolerance testing revealed insulin resistance.

260 Glucose and insulin tolerance tests revealed that lung epithelial cell-speci

261 The glucose tolerance test showed major improvement of the glucose c

262 A glucose tolerance test and insulin tolerance test showed that 25HC3S administration improve

263 Glucose tolerance tests showed that Syn-1A-betaKO mice exhibited

264 Oral glucose and insulin tolerance tests showed that the compound improves glucos

265 The 2-year mean mixed-meal tolerance test-stimulated AUC C-peptide, analyzed by ANC

266 se insulin release on an intravenous glucose tolerance test that was higher than the threshold.

267 was combined with results of an oral glucose tolerance test, the AUC reached 82.4% (80.9-83.9).

268 ecretion, as measured by intravenous glucose tolerance tests, using up to 5,567 individuals without d

269 <4.2 min) in response to intravenous glucose tolerance tests versus burst NO-releasing and control se

270 An oral glucose tolerance test was administered at discharge.

271 istance (HOMA-IR); and a 2-hour oral glucose tolerance test was administered.

272 Oral glucose tolerance test was considered the gold standard in ident

273 Intravenous glucose tolerance test was performed at baseline and at 4 and 18

274 A meal tolerance test was performed before (Pre) and after the

275 An oral-glucose-tolerance test was performed pre- and postintervention t

276 Oral glucose tolerance test was performed within 2 weeks after surger

277 Mixed-meal tolerance test was undertaken in parallel with HLA antib

278 A frequently sampled intravenous glucose tolerance test was used to obtain precise measures of ac

279 a lactose hydrogen breath test and a lactose tolerance test were performed after exclusion of primary

280 c-euglycemic clamp and a 3-hour oral glucose tolerance test were performed to evaluate insulin sensit

281 -euglycemic clamp and an intravenous glucose tolerance test were performed.

282 Lactose hydrogen breath test and lactose tolerance test were positive in all 7 patients (100%) in

283 one, vitamin D, and response to oral glucose tolerance testing were similar.

284 Oral glucose tolerance tests were administered at the same time and l

285 re collected in the morning and oral glucose tolerance tests were done in accordance with a standard

286 Intravenous glucose tolerance tests were performed 2 weeks after surgery.

287 Physical examinations and oral glucose tolerance tests were performed at baseline and after 5 y

288 Intravenous glucose tolerance tests were performed before and after 1 and 6

289 rameters and frequently sampled oral glucose tolerance tests were performed before and after interven

290 month-old offspring, and glucose and insulin tolerance tests were performed in the female offspring a

291 Body weights, plasma glucose, and insulin tolerance tests were performed prior to, immediately, an

292 ormoglycemia and adequate glucose clearance (tolerance tests) were achieved in both intrahepatic and

293 e were estimated by means of an oral glucose tolerance test, whereas peripheral insulin sensitivity a

294 KC islet grafts, postintrapertioneal glucose tolerance testing, whereas SC recipients remained hyperg

295 cipants underwent a 6-hour 75-g oral glucose tolerance test with ECG recording and blood sampling for

296 1,437 individuals underwent an oral glucose tolerance test with measurements of circulating glucose,

297 in before and during the entire oral glucose tolerance test with stimulation cycles of 30 s of on-pha

298 Oral glucose tolerance testing with glucose, insulin, and C-peptide w

299 In oral glucose tolerance tests with diet-induced obese mice, NTE-1 trea

300 sitivity, as measured by glucose and insulin tolerance tests, with intermediate effects in Nat1 heter